Local drugmakers dominate in segment of vital drugs in Russia

Print 29 March 2018
Remedium

The share of domestic drugs in the list of vital drugs available in the Russian pharmaceutical market in 2017 reached a record high of 84% for the last 20 years, according to recent statements of the Russian Minister of Industry and Trade Denis Manturov and some senior officials of the Ministry of Health, reports The Pharma Letter’s local correspondent.

Analysts predict the growth will continue this year, which may result in the increase of this figure up to 90% by the end of 2018. They also predict this will also result in a further decline of prices in the Russian market. In comparison, in 2012 only 63.5% of drugs from the list of vital in Russia were produced domestically.

Viktor Dmitriev, head of the Association of Russian Pharmaceutical Manufacturers of Russia, which unites domestic and foreign drugmakers, operating in the country, said that the increase in the share was mainly achieved due to a significant deepening of localization of drugs by foreign drugmakers which has been observed in Russia in recent years.

Executive director of the Russian National Pharmaceutical Chamber Elena Nevolina said the current demand for domestic drugs from the list of vital is high, which is mainly due to their lower prices, compared with imported analogues.
Ms Nevolina added that the difference in price may be 50% and even higher.

In accordance with the current Russian federal law "On turnover of drugs," the government establishes a maximum selling price for drugs included in the list of vital. In 2018, the list of such drugs was expanded by 68 products.

Source

Return